Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Agents: A Case Report

REFERENCES

• Norden AD, Batchelor TT. Reversible posterior leukoencephalopathy syndrome. Onkologie 2007;30:90–91.
   Google Scholar
• Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500.
   PubMed Web of Science ®Google Scholar
• Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. Am J Neuroradiol 2008;29:1036–1042.
   PubMed Web of Science ®Google Scholar
• McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS, Teksam M. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. Am J Roentgenol 2007;189:904–912.
   PubMed Web of Science ®Google Scholar
• Servillo G, Bifulco F, De Robertis E, Piazza O, Striano P, Tortora F, Striano S, Tufano R. Posterior reversible encephalopathy syndrome in intensive care medicine. Intensive Care Med 2007;33:230–236.
   PubMed Web of Science ®Google Scholar
• Lamy C, Oppenheim C, Méder JF, Mas JL. Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging 2004;14:89–96.
   PubMed Web of Science ®Google Scholar
• Pula JH, Eggenberger E. Posterior reversible encephalopathy syndrome. Curr Opin Ophthalmol 2008;19:479–484.
   PubMed Web of Science ®Google Scholar
• Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J 2005;35:83–90.
   PubMed Web of Science ®Google Scholar
• Leroux G, Sellam J, Costedoat-Chalumeau N, Le Thi Huong D, Combes A, Tieulié N, Haroche J, Amoura Z, Nieszkowska A, Chastre J, Dormont D, Piette JC. Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature. Lupus 2008;17:139–147.
   PubMed Web of Science ®Google Scholar
• Zhang YX, Liu JR, Ding MP, Huang J, Zhang M, Jansen O, Deuschl G, Eschenfelder CC. Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis. Intern Med 2008;47:867–875.
   PubMed Web of Science ®Google Scholar
• Finsterer J, Stollberger C, Ostermann E, Zuntner G, Huber J, Tscherney R. Recurrent posterior reversible encephalopathy syndrome in mitochondrial disorder. Blood Press 2009;12:1–4.
   Google Scholar
• Kahana A, Rowley HA, Weinstein JM. Cortical blindness: clinical and radiologic findings in reversible posterior leukoencephalopathy syndrome: case report and review of the literature. Ophthalmology 2005;112:e7–e11.
   Google Scholar
• Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol 2008;29:1043–1049.
   PubMed Web of Science ®Google Scholar
• Nguyen-Lam J, Kiernan MC. Acute cortical blindness due to posterior reversible encephalopathy. J Clin Neurosci 2008;15:1182–1185.
   PubMed Web of Science ®Google Scholar
• Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008;65:205–210.
   PubMed Web of Science ®Google Scholar
• Chen TY, Lee HJ, Wu TC, Tsui YK. MR imaging findings of medulla oblongata involvement in posterior reversible encephalopathy syndrome secondary to hypertension. Am J Neuroradiol 2009;30:755–757.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007;1(2 Suppl):S41–S54.
   Google Scholar
• Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807–815.
   PubMed Web of Science ®Google Scholar
• Martin G, Bellido L, Cruz, JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007;25:3559–3559.
   PubMed Web of Science ®Google Scholar
• Medioni J, Cojocarasu O, Banu E, Queudeville AC, Halimi P, Oudard S. Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Target Oncol 2007;2:193–195.
   Google Scholar
• Cumurciuc R, Martinez-Almoyna L, Henry C, Husson H, de Broucker T. Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris) 2008;164:605–720.
   PubMed Web of Science ®Google Scholar
• Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006 2;354:980–982.
   Google Scholar
• Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006 2;354:980–982.
   Google Scholar
• Allen JA, Adlakha A, Bergethon PR. Reversible Posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006;63:1475–1478.
   PubMed Web of Science ®Google Scholar
• Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007;18:1745–1747.
   PubMed Web of Science ®Google Scholar
• Levy CF, Oo KZ, Fireman F, Pierre L, Bania MA, Sadanandan S, Yamashiro DJ, Bender JL. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer 2009;52:669–671
   PubMedGoogle Scholar
• El Maalouf G, Mitry E, Lacout A, Lièvre A, Rougier P. Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol 2008;255:295–296.
   PubMed Web of Science ®Google Scholar
• Koopman M, Muller EW, Punt CJ. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case. Dis Colon Rectum 2008;51:1425–1426.
   Google Scholar
• Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43–9006. J Clin Oncol 2006;24:e48.
   Google Scholar
• Dogan E, Aksoy S, Arslan C, Dede DS, Altundag K. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.Med Oncol 2010 Dec;27:1436–1437.
   Google Scholar